相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Avi Ashkenazi et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Kevin Fitzgerald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain
Nathanael G. Lintner et al.
PLOS BIOLOGY (2017)
A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9
Amos Baruch et al.
CLINICAL CARDIOLOGY (2017)
New developments in proprotein convertase subtilisin-kexin 9's biology and clinical implications
Nabil G. Seidah
CURRENT OPINION IN LIPIDOLOGY (2016)
Disrupting the PCSK9/LDLR protein-protein interaction by an imidazole-based minimalist peptidomimetic
Mattia Stucchi et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2016)
Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptor
Colin W. Garvie et al.
PROTEIN SCIENCE (2016)
PCSK9 INHIBITORS: MONOCLONAL ANTIBODIES FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
D. M. Paton
DRUGS OF TODAY (2016)
A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation
Donna N. Petersen et al.
CELL CHEMICAL BIOLOGY (2016)
Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial
Eveline P. van Poelgeest et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era
M. John Chapman et al.
CURRENT OPINION IN LIPIDOLOGY (2015)
Design and Synthesis of Truncated EGF-A Peptides that Restore LDL-R Recycling in the Presence of PCSK9 In Vitro
Christina I. Schroeder et al.
CHEMISTRY & BIOLOGY (2014)
Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing
Qiurong Ding et al.
CIRCULATION RESEARCH (2014)
Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor
Yingnan Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management
Gergana Galabova et al.
PLOS ONE (2014)
Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics
Evan A. Stein et al.
CURRENT ATHEROSCLEROSIS REPORTS (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels
Michael T. Lipari et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Calcium-Independent Inhibition of PCSK9 by Affinity-Improved Variants of the LDL Receptor EGF(A) Domain
Yingnan Zhang et al.
JOURNAL OF MOLECULAR BIOLOGY (2012)
The biology and therapeutic targeting of the proprotein convertases
Nabil G. Seidah et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Data processing and analysis with the autoPROC toolbox
Clemens Vonrhein et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2011)
REFMAC5 for the refinement of macromolecular crystal structures
Garib N. Murshudov et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2011)
Overview of the CCP4 suite and current developments
Martyn D. Winn et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2011)
XDS
Wolfgang Kabsch
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
Features and development of Coot
P. Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Paul D. Adams et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2010)
The crystal structures of two cuticle-degrading proteases from nematophagous fungi and their contribution to infection against nematodes
Lianming Liang et al.
FASEB JOURNAL (2010)
Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants
Matthew J. Bottomley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
PCSK9: a convertase that coordinates LDL catabolism
Jay D. Horton et al.
JOURNAL OF LIPID RESEARCH (2009)
Molecular basis for LDL receptor recognition by PCSK9
Hyock Joo Kwon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domain
Eric N. Hampton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity
Jun Li et al.
BIOCHEMICAL JOURNAL (2007)
Phaser crystallographic software
Airlie J. McCoy et al.
JOURNAL OF APPLIED CRYSTALLOGRAPHY (2007)
Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells
Markey C. McNutt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
David Cunningham et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library
We-Ching Liang et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Identifying specificity profiles for peptide recognition modules from phage-displayed peptide libraries
Raffi Tonikian et al.
NATURE PROTOCOLS (2007)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs
Kerry Zobel et al.
ACS CHEMICAL BIOLOGY (2006)
Peptidomimetics - Antagonists of the fibrinogen receptors: Molecular design, structures, properties and therapeutic applications
SA Andronati et al.
CURRENT MEDICINAL CHEMISTRY (2004)
High-affinity human antibodies from phage-displayed synthetic fab libraries with a single framework scaffold
CV Lee et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Bivalent antibody phage display mimics natural immunoglobulin
CV Lee et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP)
MC Franklin et al.
BIOCHEMISTRY (2003)
The crystal structure of the proprotein processing proteinase furin explains its stringent specificity
S Henrich et al.
NATURE STRUCTURAL BIOLOGY (2003)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Structure of a serine protease proteinase K from Tritirachium album limber at 0.98 Å resolution
C Betzel et al.
BIOCHEMISTRY (2001)
分享论文
